292 related articles for article (PubMed ID: 21079811)
1. ER-α36, a novel variant of ER-α, mediates estrogen-stimulated proliferation of endometrial carcinoma cells via the PKCδ/ERK pathway.
Tong JS; Zhang QH; Wang ZB; Li S; Yang CR; Fu XQ; Hou Y; Wang ZY; Sheng J; Sun QY
PLoS One; 2010 Nov; 5(11):e15408. PubMed ID: 21079811
[TBL] [Abstract][Full Text] [Related]
2. ER-alpha36, a variant of ER-alpha, promotes tamoxifen agonist action in endometrial cancer cells via the MAPK/ERK and PI3K/Akt pathways.
Lin SL; Yan LY; Zhang XT; Yuan J; Li M; Qiao J; Wang ZY; Sun QY
PLoS One; 2010 Feb; 5(2):e9013. PubMed ID: 20126312
[TBL] [Abstract][Full Text] [Related]
3. A novel variant of ER-alpha, ER-alpha36 mediates testosterone-stimulated ERK and Akt activation in endometrial cancer Hec1A cells.
Lin SL; Yan LY; Liang XW; Wang ZB; Wang ZY; Qiao J; Schatten H; Sun QY
Reprod Biol Endocrinol; 2009 Sep; 7():102. PubMed ID: 19775474
[TBL] [Abstract][Full Text] [Related]
4. ER-α36, a novel variant of estrogen receptor α, is involved in EGFR-related carcinogenesis in endometrial cancer.
Tu BB; Lin SL; Yan LY; Wang ZY; Sun QY; Qiao J
Am J Obstet Gynecol; 2011 Sep; 205(3):227.e1-6. PubMed ID: 21684519
[TBL] [Abstract][Full Text] [Related]
5. Estrogen receptor-α variant, ER-α36, is involved in tamoxifen resistance and estrogen hypersensitivity.
Zhang X; Wang ZY
Endocrinology; 2013 Jun; 154(6):1990-8. PubMed ID: 23546601
[TBL] [Abstract][Full Text] [Related]
6. ER-α36 mediates estrogen-stimulated MAPK/ERK activation and regulates migration, invasion, proliferation in cervical cancer cells.
Sun Q; Liang Y; Zhang T; Wang K; Yang X
Biochem Biophys Res Commun; 2017 Jun; 487(3):625-632. PubMed ID: 28435071
[TBL] [Abstract][Full Text] [Related]
7. Estrogen activation of the mitogen-activated protein kinase is mediated by ER-α36 in ER-positive breast cancer cells.
Zhang X; Deng H; Wang ZY
J Steroid Biochem Mol Biol; 2014 Sep; 143():434-43. PubMed ID: 24973581
[TBL] [Abstract][Full Text] [Related]
8. ER-α36 mediates cisplatin resistance in breast cancer cells through EGFR/HER-2/ERK signaling pathway.
Zhu L; Zou J; Zhao Y; Jiang X; Wang Y; Wang X; Chen B
J Exp Clin Cancer Res; 2018 Jun; 37(1):123. PubMed ID: 29940998
[TBL] [Abstract][Full Text] [Related]
9. Synuclein gamma stimulates membrane-initiated estrogen signaling by chaperoning estrogen receptor (ER)-alpha36, a variant of ER-alpha.
Shi YE; Chen Y; Dackour R; Potters L; Wang S; Ding Q; Wang Z; Liu YE
Am J Pathol; 2010 Aug; 177(2):964-73. PubMed ID: 20595634
[TBL] [Abstract][Full Text] [Related]
10. A variant of estrogen receptor-{alpha}, hER-{alpha}36: transduction of estrogen- and antiestrogen-dependent membrane-initiated mitogenic signaling.
Wang Z; Zhang X; Shen P; Loggie BW; Chang Y; Deuel TF
Proc Natl Acad Sci U S A; 2006 Jun; 103(24):9063-8. PubMed ID: 16754886
[TBL] [Abstract][Full Text] [Related]
11. Estrogen receptor-α36 is involved in pterostilbene-induced apoptosis and anti-proliferation in in vitro and in vivo breast cancer.
Pan C; Hu Y; Li J; Wang Z; Huang J; Zhang S; Ding L
PLoS One; 2014; 9(8):e104459. PubMed ID: 25127034
[TBL] [Abstract][Full Text] [Related]
12. Estrogen receptor-α36 is involved in development of acquired tamoxifen resistance via regulating the growth status switch in breast cancer cells.
Li G; Zhang J; Jin K; He K; Zheng Y; Xu X; Wang H; Wang H; Li Z; Yu X; Teng X; Cao J; Teng L
Mol Oncol; 2013 Jun; 7(3):611-24. PubMed ID: 23499324
[TBL] [Abstract][Full Text] [Related]
13. G protein-coupled receptor 30-dependent protein kinase A pathway is critical in nongenomic effects of estrogen in attenuating liver injury after trauma-hemorrhage.
Hsieh YC; Yu HP; Frink M; Suzuki T; Choudhry MA; Schwacha MG; Chaudry IH
Am J Pathol; 2007 Apr; 170(4):1210-8. PubMed ID: 17392161
[TBL] [Abstract][Full Text] [Related]
14. Involvement of estrogen receptor variant ER-alpha36, not GPR30, in nongenomic estrogen signaling.
Kang L; Zhang X; Xie Y; Tu Y; Wang D; Liu Z; Wang ZY
Mol Endocrinol; 2010 Apr; 24(4):709-21. PubMed ID: 20197310
[TBL] [Abstract][Full Text] [Related]
15. Biphasic ER-α36-mediated estrogen signaling regulates growth of gastric cancer cells.
Wang X; Huang X; Fu Z; Zou F; Li Y; Wang Z; Liu L
Int J Oncol; 2014 Dec; 45(6):2325-30. PubMed ID: 25231129
[TBL] [Abstract][Full Text] [Related]
16. Estrogen receptor-α36 is involved in icaritin induced growth inhibition of triple-negative breast cancer cells.
Wang X; Zheng N; Dong J; Wang X; Liu L; Huang J
J Steroid Biochem Mol Biol; 2017 Jul; 171():318-327. PubMed ID: 28529129
[TBL] [Abstract][Full Text] [Related]
17. ER-alpha36, a novel variant of ER-alpha, is expressed in ER-positive and -negative human breast carcinomas.
Lee LM; Cao J; Deng H; Chen P; Gatalica Z; Wang ZY
Anticancer Res; 2008; 28(1B):479-83. PubMed ID: 18383888
[TBL] [Abstract][Full Text] [Related]
18. Estrogen receptor-alpha 36 mediates mitogenic antiestrogen signaling in ER-negative breast cancer cells.
Zhang X; Ding L; Kang L; Wang ZY
PLoS One; 2012; 7(1):e30174. PubMed ID: 22276155
[TBL] [Abstract][Full Text] [Related]
19. [Nongenomic effects of estrogen on extracellular signal-regulated kinases through initiating transient calcium flux in endometrial cancer].
Zhang LL; Wang JL
Beijing Da Xue Xue Bao Yi Xue Ban; 2015 Jun; 47(3):489-93. PubMed ID: 26080881
[TBL] [Abstract][Full Text] [Related]
20. [Estradiol activates MAPK signaling pathway by estrogen induced VEGF and bFGF in endometrial cancer cells].
Lu Y; Jiang S; Zhang J; Song H; Li L
Zhonghua Fu Chan Ke Za Zhi; 2014 Dec; 49(12):925-31. PubMed ID: 25608994
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
